Benitec Biopharma Reports $12.9 Million Quarterly Loss

The Hayward-based biopharma company posted its first fiscal quarter 2027 results and announced positive interim data for its BB-301 candidate.

Updated on Nov. 13, 2026 in Corporate Finance

Isometric editorial illustration of unlabeled amber vials in a steel rack on a laboratory bench, evoking biotech research spending.
Benitec Biopharma reported a $12.9 million net loss for the quarter ended September 30, 2026, while announcing positive interim results for its BB-301 candidate. AI Illustration. Upload story photo >

Benitec Biopharma reported first fiscal quarter 2027 financial results for the period ended September 30, 2026, with total expenses of $14.5 million and a net loss of $12.9 million, or $(0.26) per share. The company also announced positive interim clinical results for BB-301 at the ESGCT Annual Congress.

Why it matters

The results show the company's spending is concentrated on developing BB-301 for oculopharyngeal muscular dystrophy, with cash reserves of $176.5 million funding the program. Interim data showing a 100% responder rate and no Serious Adverse Events to date could shape investor expectations as the company moves toward a pivotal trial.

Net loss per basic and diluted share was $(0.26) for the quarter, against 34,889,313 common shares outstanding at September 30, 2026. Cash and cash equivalents of $176.5 million compare with a quarterly net loss of $12.9 million, and the company has not disclosed how long that cash position will fund operations under the planned pivotal trial.

The players

Benitec Biopharma Inc.

Benitec Biopharma is a Hayward, California-based clinical-stage biopharmaceutical company developing gene silencing therapies, including its lead candidate BB-301 for oculopharyngeal muscular dystrophy.

The details

Research and development expenses were $8.6 million and general and administrative expenses were $5.9 million for the quarter. Interim BB-301 results presented at the ESGCT Annual Congress in Hamburg, Germany, showed a 100% responder rate across Cohort 1 and Cohort 2 patients, and the company plans to change its fiscal year-end from June 30 to December 31.

Timeline

  1. September 30, 2026: First fiscal quarter 2027 ends, the reporting period for these results.

  2. October 28, 2026: BB-301 interim results presented at the ESGCT Annual Congress.

  3. November 13, 2026: Benitec reports first fiscal quarter 2027 financial results.

  4. First calendar quarter of 2027: Pivotal study design expected to be finalized.

  5. Mid-2027: Company expects to begin the pivotal trial.

Market Dynamics

The company's spending profile reflects its single-program focus on the BB-301 gene silencing construct for oculopharyngeal muscular dystrophy, a rare disease area where its orphan drug designations from the EMA and FDA may shape its path to market. Its planned move to a December 31 fiscal year-end aligns its reporting with calendar-year peers in the sector.

Shareholders holding Benitec's roughly 34.9 million common shares face a quarterly net loss of $0.26 per share, and the timing of the pivotal trial will determine when the company's spending pattern is likely to change. Investors tracking the stock should watch the finalized pivotal study design and the company's cash runway disclosures in coming filings.

The takeaway

Benitec's results show a company whose near-term value rests on whether BB-301's early responder data holds up in a larger pivotal study. Investors should track the finalized trial design and future cash-burn disclosures to judge progress.

What happens next

Benitec expects to finalize the pivotal study design in the first calendar quarter of 2027 and begin the pivotal trial in mid-2027, and will change its fiscal year-end to December 31 with its first periodic report following the Form 10-Q for the quarter ended September 30, 2026.

Further reading

For more on how companies report and fund their operations, explore Corporate Finance coverage.

Source note: This article includes information reported by The Manila times.